万泰生物跌2.02%，成交额1.31亿元，主力资金净流出1736.87万元

Core Viewpoint - Wante Bio's stock has experienced a significant decline in 2023, with a year-to-date drop of 31.73% and a recent 60-day decline of 17.40% [2] Company Overview - Wante Bio, established on April 24, 1991, and listed on April 29, 2020, is located in Changping District, Beijing. The company specializes in the research, production, and sales of in vitro diagnostic reagents, instruments, and vaccines [2] - The revenue composition of Wante Bio includes: diagnostic reagents (67.06%), vaccines (20.36%), diagnostic instruments (4.98%), agency products (4.97%), other (1.88%), and active raw materials (0.76%) [2] - As of September 30, 2025, Wante Bio had 42,000 shareholders, an increase of 9.41% from the previous period, with an average of 30,124 circulating shares per shareholder, a decrease of 8.60% [2] Financial Performance - For the period from January to September 2025, Wante Bio reported a revenue of 1.498 billion yuan, a year-on-year decrease of 23.09%, and a net profit attributable to shareholders of -173 million yuan, a year-on-year decrease of 165.04% [2] - Since its A-share listing, Wante Bio has distributed a total of 1.541 billion yuan in dividends, with 1.311 billion yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the top ten circulating shareholders of Wante Bio include Hong Kong Central Clearing Limited, which holds 12.8991 million shares (a decrease of 9.8553 million shares), and Huatai-PB CSI 300 ETF, holding 6.4061 million shares (a decrease of 318,300 shares) [3] - The China National Securities Bio-Medical Index A has entered the top ten circulating shareholders with 4.9609 million shares as a new shareholder, while E Fund CSI 300 Medical ETF has exited the list [3] Market Activity - On November 28, Wante Bio's stock price fell by 2.02%, trading at 48.10 yuan per share, with a total transaction volume of 131 million yuan and a turnover rate of 0.21%. The total market capitalization is 60.852 billion yuan [1] - In terms of capital flow, there was a net outflow of 17.3687 million yuan from main funds, with large orders showing a buy of 23.094 million yuan (17.66%) and a sell of 27.222 million yuan (20.82%) [1]